ArticleBMC immunology2026
Early diagnostic value of serum procalcitonin, C-reactive protein, white blood cell count and the neutrophil percentage in bacterial and fungal bloodstream infections.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and external validation of a machine learning model for predicting gangrenous cholecystitis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSIs) are severe systemic disorders caused by pathogenic microorganisms, including bacteria and fungi, invading the bloodstream. Associated with high morbidity and mortality, BSIs represent one of the leading causes of death globally. There is an urgent demand for simple, rapid, and accurate laboratory biomarkers to facilitate the diagnosis and differential diagnosis of patients with suspected BSIs, thereby guiding timely and targeted antimicrobial therapy.
objectiveTo evaluate the value of serum procalcitonin (PCT), C-reactive protein (CRP), white blood cell count (WBC), and neutrophil percentage (NEUT%) for early and differential diagnosis of bacterial vs. fungal bloodstream infections (BSIs), a cross-sectional study was conducted.
methodsA total of 1649 patients with suspected BSI were included in this retrospective study. Of these, 1357 patients with positive blood cultures were classified as the BSI group (experimental group), and 292 patients with negative blood cultures were assigned to the non-BSI group (control group). Serum PCT, CRP, WBC/NEUT% were measured using a bioMerieux VIDAS 30 analyzer, SIEMENS ADVIA 2400 and by Sysmex XN-9000, respectively. Microbial identification was based on bioMerieux VITEK 2 systems. The diagnostic performance of these biomarkers in the discrimination in bacterial and fungal bloodstream infections were compared using receiver operating characteristic (ROC) curves.
resultsFor BSI discrimination, a PCT level > 0.687 ng/mL could demonstrate the optimal performance (AUC = 0.788, sensitivity 61.7%, specificity 80.1%). The PCT level < 0.5 ng/mL for 3 consecutive days could effectively rule out BSI (sensitivity 98.1%, specificity 79.5%). Elevated PCT (> 1.78 ng/mL) and CRP (> 79.76 mg/L) levels were associated with bacterial BSIs (AUC = 0.686 for the combined markers). A PCT level > 1.98 ng/mL suggested Gram-negative BSI (sensitivity 68.4%). The positive diagnostic rates of the PCT + CRP+NEUT% combined test for G- bacterial and G+ bacterial BSIs reached 96.17% and 92.86% respectively, which significantly improved the diagnostic positive rate compared with single diagnosis.
conclusionsPCT could reliably excludes BSI (3-day < 0.5 ng/mL rule) and aids differentiation (bacterial/fungal: PCT + CRP; G-/G+: PCT+NEUT%). Multi-parameter approaches optimize diagnostic accuracy for timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.